NDA 211321 · Ucb INC
Nayzilam
Midazolam · Nasal · Benzodiazepine
OrphanLast checked: Nov 20, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
May 17, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,448
153 Phase 3, 96 recruiting
FAERS reports
25,623
23,715 serious, 4,786 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death . Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) and Drug Interactions (7.2) ] . The use of benzodiazepines, including NAYZILAM, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse...
What it is approved for
From the label in effect Oct 16, 2026.
NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older. NAYZILAM is a benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older. ( 1 )
Mechanism: The exact mechanism of action for midazolam is not fully understood, but it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABA A receptor.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 17, 2019 Original approval · Type 3 - New Dosage Form OrphanLabelMedication GuideLetter
1 products under this application
- NAYZILAM · MIDAZOLAM 5MG/SPRAY · SPRAY, NASAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Midazolam" as an intervention, any sponsor and status, largest first.
- Pediatric Dose Optimization for Seizures in Emergency Medical ServicesPivotal-lookingCompleted
Stanford UniversityAcademic, hospital or other
NCT05121324 · 6,897 participants · Start Aug 8, 2022 · Primary completion Jul 31, 2026
Drug: Standardized seizure protocol; Conventional seizure protocol · For: Seizures
Sites: Tucson, Arizona; Los Angeles, California; Sacramento, California · 20 sites in all
- Anesthesia and Non-small Cell Lung Cancer RecurrencePivotal-lookingRecruiting
Samsung Medical CenterAcademic, hospital or other
NCT06330038 · 5,384 participants (planned) · Start Aug 5, 2024 · Primary completion Dec 31, 2028
Drug: Propofol; Inhaled anesthetics · For: Non-small Cell Lung Cancer; Surgery; Anesthesia
Sites: Seoul, South Korea
- To Relieve Pain and Anxiety - an Intervention Study in Ambulance ServicesPivotal-lookingCompleted
Sahlgrenska University HospitalAcademic, hospital or other
NCT00792181 · 2,800 participants (planned) · Start Jun 2008 · Primary completion Nov 2008
Drug: Midazolam · For: Acute Myocardial Infarction; Pain
- the Research of Analgesia and Sedation Effect of Remifentanil on ICU Short OperationPivotal-lookingStatus unknown
The First Affiliated Hospital of Zhengzhou UniversityAcademic, hospital or other
NCT02635802 · 1,500 participants (planned) · Start Dec 2015 · Primary completion Jun 2016
Drug: Remifentanil; Lidocaine and 2 more · For: Critical Illness
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsPivotal-lookingRecruiting
ExelixisIndustry
NCT05176483 · 1,394 participants (planned) · Start Dec 14, 2021 · Primary completion Jan 31, 2027
Drug: Zanzalintinib; Nivolumab and 5 more · For: Renal Cell Carcinoma (RCC); Metastatic Castration-Resistant Prostate Cancer (mCRPC); Urothelial Carcinoma (UC) and 8 more
Sites: Phoenix, Arizona; Tucson, Arizona; Palo Alto, California · 122 sites in all
- Impact of Anesthesia Maintenance Methods on 5-year Survival After SurgeryPivotal-lookingCompleted
Peking University First HospitalAcademic, hospital or other
NCT05343260 · 1,228 participants · Start Apr 1, 2015 · Primary completion Sep 30, 2022
Drug: Sevoflurane; Propofol · For: Aged; Neoplasms; Surgical Procedure, Operative and 3 more
Sites: Beijing, China; Nanning, China; Guiyang, China · 15 sites in all
- Impact of Anesthesia Maintenance Methods on Long-term SurvivalPivotal-lookingCompleted
Peking University First HospitalAcademic, hospital or other
NCT02660411 · 1,228 participants · Start Apr 1, 2015 · Primary completion Sep 29, 2017
Drug: Sevoflurane; Propofol · For: Aged; Neoplasms; Surgical Procedure, Operative and 3 more
Sites: Beijing, China; Nanning, China; Shenzhen, China · 17 sites in all
- A Prospective, Multi-center, Randomized Controlled Study of Muscle Relaxation Effect and Safety of Mivacurium Chloride in Pediatric Surgery PatientsPivotal-lookingCompleted
Jiangsu Nhwa Pharmaceutical Co., Ltd.Industry
NCT02117401 · 1,152 participants · Start Jan 2012 · Primary completion Jun 2013
Drug: mivacurium chloride; midazolam and 3 more · For: Efficacy and Safety of Mivacurium Chloride for Pediatric Patients
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective3,208
- off label use2,487
- seizure1,639
- hypotension1,399
- drug interaction1,152
- acute kidney injury895
- toxicity to various agents881
- pyrexia858
- cardiac arrest853
- death720
- status epilepticus670
- condition aggravated655
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 58 |
| 2005 | 155 |
| 2006 | 119 |
| 2007 | 25 |
| 2008 | 32 |
| 2009 | 42 |
| 2010 | 110 |
| 2011 | 321 |
| 2012 | 723 |
| 2013 | 724 |
| 2014 | 814 |
| 2015 | 1,068 |
| 2016 | 1,173 |
| 2017 | 1,339 |
| 2018 | 1,686 |
| 2019 | 1,933 |
| 2020 | 2,254 |
| 2021 | 2,623 |
| 2022 | 1,999 |
| 2023 | 2,356 |
| 2024 | 2,168 |
| 2025 | 2,361 |
| 2026 | 1,540 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nayzilam (Midazolam)
2024 spending
$36.9M
Beneficiaries
18,184
39,175 claims
Per beneficiary
$2,027
$327.23 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,483,915 |
| 2021 | $11,990,591 |
| 2022 | $18,754,348 |
| 2023 | $27,518,709 |
| 2024 | $36,864,379 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Interaction of herbal products with prescribed medications: A systematic review and meta-analysis.
Awortwe C, Bruckmueller H, Cascorbi I · Pharmacol Res 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- A systematic review and meta-analysis of propofol versus midazolam sedation in adult intensive care (ICU) patients.
Garcia R, Salluh JIF, Andrade TR, et al. · J Crit Care 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials.
Jakob SM, Ruokonen E, Grounds RM, et al. · JAMA 2012 · Comparative Study, Multicenter Study
- Remimazolam for procedural sedation: A systematic review with meta-analyses and trial sequential analyses.
Pingel L, Maagaard M, Tvarnø CD, et al. · Eur J Anaesthesiol 2025 · Systematic Review, Meta-Analysis
- Optimizing pediatric premedication for general anesthesia: A comprehensive Bayesian network meta-analysis.
Wegner GRM, Wegner BFM, Cumming HS, et al. · J Clin Anesth 2025 · Network Meta-Analysis, Systematic Review
- A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy.
Rex DK, Bhandari R, Desta T, et al. · Gastrointest Endosc 2018 · Clinical Trial, Phase II, Comparative Study
Sponsor: UCB
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.